Check Claims Before You Publish

Author Review: Zhuanting Ye — Visual, Evidence‑first Appraisal

Representative high-quality items (selected)

• Engineered probiotics: a new era in treating inflammatory bowel disease — open-access 2025 translational review mapping engineered microbes → therapeutic pipelines and challenges; useful synthesis for IBD translation (Engineered probiotics (2025))
• Angewandte Chemistry 2023 coauthorship — ferrocene-based NIR-II‑tracked chemodynamic nanomedicine showcasing cross-disciplinary capability (Angewandte nanomedicine (2023))
• Oncogene 2015 — mechanistic molecular biology on estrogen-responsive transcription; demonstrates past involvement in mechanistic bench science (Oncogene transcription (2015))

Evidence-strength synthesis (key points)

1. Productive, multidisciplinary collaborator: Titles and the presence of high‑impact coauthored items (Angewandte, Oncogene, Translational Medicine review) indicate Z. Ye works across clinical and basic/translational teams; however many contributions appear as middle authors, consistent with collaborative but not necessarily PI‑led role (Angewandte nanomedicine (2023))
2. Clinical focus with translational interest: Multiple papers centre on Crohn's disease, diagnostic ultrasonography, surgical technique, and IBD immunotherapy — consistent with a clinical/translational focus and application‑driven research questions (Engineered probiotics (2025))
3. Modest citation impact overall: Given ~23 papers and ~50 citations (h≈5), citation density is low-to-modest — consistent with early/mid career or clinically-focused publication venues that attract fewer citations than fundamental biology papers; individual high‑impact coauthored items partly offset this (Oncogene transcription (2015))

Critical limitations, blindspots and biases

• No persistent public institutional affiliation or ORCID visible in supplied metadata — reduces traceability and reproducibility for author‑level attribution (OpenAlex entry shows possible name variants and differing metrics which could indicate conflation risk).
• Many middle-author roles; limited evidence of sustained PI‑led, hypothesis-driven solo projects or large randomized clinical trials under direct authorship — suggests strength as collaborator rather than independent research leader.
• Heterogeneous topics (from materials chemistry to clinical surgery) raise possibility of name ambiguity across fields or collaboration across labs — verify identity with institutional profile/ORCID to avoid attribution errors (OpenAlex shows similar names like Zhuangjie Ye contributing to chemistry/physics topics).
• Bibliometrics (h-index, citations) are modest; small-sample effects, variable citation windows, and clinical‑specialty citation practices affect interpretation — do not overinterpret low citation numbers as lack of value, but they set realistic expectations about influence.

Actionable recommendations to strengthen scientific profile

1. Obtain and consistently use an ORCID and institutional page to disambiguate identity and link publications; this reduces conflation across names and improves discoverability.
2. Lead prospective translational studies or randomized/prospective cohorts in the clinical domain (e.g., investigator‑initiated Crohn's disease cohorts) and place emphasis on pre-registering protocols to increase leadership evidence and citation traction.
3. When coauthoring multidisciplinary work, if feasible, take first or corresponding author roles on at least 1–2 papers that articulate clear independent hypotheses and experimental ownership to show PI/lead capacity.
4. Target systematic, reproducible reporting (data sharing, methods detail) and choose journals with reasonable discoverability (indexing, open access) to improve citation uptake over time.

Representative citations (selected)

• Engineered probiotics (2025)
• Angewandte nanomedicine (2023)
• Oncogene transcription (2015)

Confidence note: conclusions emphasize author as multidisciplinary collaborator with clinical-translational focus; evidence is limited by name-disambiguation risk and moderate bibliometric impact — verify identity with ORCID/institutional profile for definitive attribution.